Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus mycophenolate mofetil for proliferative lupus nephritis
MOH_2017-07-08_000609Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of obinutuzumab, sponsored by Roche. Started Aug 2015; status: active, not recruiting.
02
Drugs
obinutuzumab
Beyond the preview
Go deeper on MOH_2017-07-08_000609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-08_000609.